GSK Stock is A bit Undervalued RIght now.. Institutions have price targets of 42~-48
back on the Covid-low-trendline .. I dont see much Downside as Compared to upside.
Dip below 35.99 ~ 35.70 range Twice , back up to 36.30 <---- 50+ cent gap ups.
With Covid vaccine News coming any day now - Its this could be the next play.
No matter which company has the...
even without vaccine considiration, GSK is good business with price at multiyear bottom zone. Started in september trials on vaccine, later in oct progress would be more clear, still there are no factors for price go lower.
Put tight stop loss under 37.
Next support level is 35, so if 37 would be broken and retested - take short position.
see full chart at www.tradingview.com
Target 1 $42.45
Target 2 $45.50
Target 3 $48
Why this play?
There are 4 general approaches to the Covid vaccine.
1.A "killed" coronavirus that will get recognized as foreign matter in the blood. (Sinovac/Dynavax)
2.Coronavirus proteins themselves, produced industrially in...
Right now, I am bullish on $GSK and expect a breakout for the Covid19 vaccines period. I think it is also garnishing some momentum, positive sentiment and major support levels. The charting is for a positive continuation of the current wedge. That being said, everything I say is on an opinion based basis. Please proceed with caution, invest at your own discretion...
Average Recommendation: HOLD
Average Target Price: 41.60
P/E ratio 17
GSK is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer...
An intraday high potential, Back Tested Sort Analysis.
We ll try to enter into the correction of the uptrend movement.
DETAILS ON THE CHART
NOTE: Entry range area above the entry point, is calculated upon 80% of the recorded pullback back tested past performances
DISCLAIMER: This is a technical analysis study, not an advice or recommendation to invest money on.
Short from $42.01.
- Market Cap: $102B
- Beta: 0.83
- P/B: 20.42
- GSK’s consumer healthcare segment sales were down in 2017 due to a slowdown in global growth of its key consumer categories.
- They have also faced pricing pressure from competition and slow down in emerging markets. Although GSK have several candidates in different stages of development, the...
I'm long in the long-run, short in the short run. The RSI on the longer term chart shows we're a bit overbought, and history tells us this results in a ~2% correction. We're seeing divergances where we'd expect them to confirm that. A nice coincidence is that the 37.4 target for a 2% drop is also a good support line.
Wait for a confirmation of a bounce around...
Since our last bullish outlook on the pharmeceutical sector, Revelation Trading feels that this is one stock to look out for. Though it has caused a slight dent, the failure of Congress to repeal and replace Obamacare has not caused the pharmaceutical stocks in our radar to tumble. In fact, they have held their well defined ranges. That to us, is strength.
A few week duration Long here.
GSK seems to be hitting symmetry in the last timeframe.
There's some remaining price structure to balance out from the 37 levels.
The market knows 37 it can find buyers, it doesn't know 2x as far away at 45.50 if it can find sellers again.
I believe it needs to see 45.50 before it can test the VPOC lower or move lower back to 37 and...